Clinical trials: Experimental Group
Diphtheria, Tetanus
Study of DTaP-IPV-Hep B-PRP~T Combined Vaccine in Indian Infants Previously Given a Dose of Hepatitis B Vaccine at Birth
The purpose of this study is to describe the immunogenicity and safety of a novel DTaP- IPV- Hep B-PRT~T fully liquid combined hexavalent vaccine (Hexaxim™) administered at 6, 10 and 14 weeks of age in infants born to mothers…
- Conditions
- Diphtheria, Tetanus, Whooping Cough, Hepatitis B
- Trial name
- NCT01948193
- Testing
- Hexaxim™: DTaP-IPV-Hep B-PRP~T combined vaccine
- Where
- 2 sites in India
- Volunteers
- 177 people, healthy volunteers welcome
- Sponsor
- Sanofi Pasteur, a Sanofi Company
Sensorineural Hearing Loss
Evaluation of Extended Wear Hearing Aid for Mild Hearing Loss
This study will assess the benefit of extended wear hearing aids for subjective listening effort, compared to the unaided condition, in adults with mild sensorineural hearing loss.
- Trial name
- NCT06746038
- Testing
- Extended Wear Hearing Aid
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Sonova AG
Migraine
The Evaluation of the Transcutaneous Electrical Stimulation Medical Device's Safety and Effectiveness in Treating the Patients With Migraine
The purpose of this study is to investigate the safety and effectiveness of trigeminal nerve electrical stimulator on reducing the frequency of migraine onset.
- Trial name
- NCT05301920
- Testing
- Elexir (trigeminal nerve electrical stimulator)
- Where
- South Korea
- Volunteers
- 20 people
- Sponsor
- Nu Eyne Co., Ltd.
COVID-19
A Clinical Trial of Recombinant COVID-19 Bivalent (XBB+Prototype) Protein Vaccine (Sf9 Cell) in Booster Vaccination
A Clinical Trial of Recombinant COVID-19 Bivalent (XBB+Prototype) Protein Vaccine (Sf9 Cell) in Booster Vaccination to evaluate safety and immunogenicity in healthy population aged 18 years old and above.
- Trial name
- NCT05911048
- Testing
- Recombinant COVID-19 Bivalent (XBB+Prototype) Protein Vaccine (Sf9 Cell) (WSK-V101C), Recombinant COVID-19 vaccine(Sf9 Cell) (WSK-V101)
- Volunteers
- 3,100 people, healthy volunteers welcome
- Sponsor
- WestVac Biopharma Co., Ltd.
Rhinosinusitis, Rhinitis
Safety and Efficacy of DSM 32444 Postbiotic in the Treatment of Acute Rhinosinusitis
Rhinitis is a type of upper respiratory infection with a common nasal pathology especially in Southeast Asia, which is characterized by the presence of one or more of the following symptoms: itchy nose, sneezing, runny nose, and…
- Trial name
- NCT05999955
- Testing
- Neomycin/ Dexameythasone/Xylometazoline, Bacillus subtilis DSM32444
- Where
- Vietnam
- Volunteers
- 60 people
- Sponsor
- Huro Biotech Joint Stock Company
Colorectal (Colon or Rectal) Cancer
A Phase Ⅱ/Ⅲ Clinical Trial of RC148 Plus Chemotherapy as 1L Therapy for Unresectable or Metastatic Colorectal Cancer
This is a Phase Ⅱ/Ⅲ study. The purpose of this study is to evaluate the efficacy and safety of RC148 combined with chemotherapy for the first-line treatment of unresectable metastatic colorectal cancer (CRC)
- Trial name
- NCT07462143
- Testing
- RC148 (Dose 1) plus Capecitabine and Oxaliplatin, RC148 (Dose 2) plus Capecitabine and Oxaliplatin
- Where
- 19 sites in China
- Volunteers
- 80 people
- Sponsor
- RemeGen Co., Ltd.
Chronic Hepatitis b, Liver Inflammation
Magnesium Isoglycyrrhizinate Followed by Diammonium Glycyrrhizinate and Combined With Entecavir in Chronic Hepatitis B
This study evaluates the addition of glycyrrhizin to entecavir in the treatment of patients with chronic hepatitis B in China. Half of participants will receive magnesium isoglycyrrhizinate followed by oral diammonium…
- Trial name
- MAGIC-101 (NCT03349008)
- Testing
- Entecavir, Magnesium Isoglycyrrhizinate, Diammonium Glycyrrhizinate
- Volunteers
- 480 people
- Sponsor
- Cttq
HIV Infections, COVID-19
Immunogenicity and Safety of an Inactivated COVID-19 Vaccine in People Aged ≥18 Years With HIV Infected
Evaluation of immunogenicity and safety of the subjects aged 18 years and above with HIV-infected recruited to receive three doses of inactivated COVID-19 vaccine on day 0, day 21 and day 111, respectively .
- Trial name
- NCT05075044
- Testing
- Inactivated COVID-19 vaccine
- Where
- China
- Volunteers
- 400 people
- Sponsor
- China National Biotec Group Company Limited
Infertility, Female
Automated Intracytoplasmic Sperm Injection (ICSIA)
The purpose of this research study is to evaluate Overture's automated Intracytoplasmic Sperm Injection (ICSIA) System. ICSIA is an investigational medical device that automates injection of sperm into eggs.
- Trial name
- ICSIA (NCT05633316)
- Testing
- Investigational device named ICSIA, Manual ICSI
- Where
- United States
- Volunteers
- 10 people, healthy volunteers welcome
- Sponsor
- Overture Life
Relapsing Remitting Multiple Sclerosis
Safety Study of Olesoxime in Patients With Stable Relapsing Remitting Multiple Sclerosis Treated With Interferon Beta.
This is a 24-week phase 1b, randomized, double-blind, placebo-controlled, parallel-group, multicenter safety study comparing the tolerance profile of olesoxime (495 mg, od) when administered on top of Interferon beta in patients…
- Trial name
- MSREPAIR (NCT01808885)
- Testing
- olesoxime (TRO19622)
- Where
- 3 sites in France
- Volunteers
- 44 people
- Sponsor
- Hoffmann-La Roche
Pulse Oximetry
SpO2 Validation Study - Philips FAST 2024
Validation study to compare the accuracy of non-invasive Philips SpO2 sensors in detecting blood oxygen levels compared to invasive methods requiring a blood draw and lab analysis.
- Trial name
- FAST 2024 (NCT06484452)
- Testing
- No Intervention
- Where
- United States
- Volunteers
- 113 people, healthy volunteers welcome
- Sponsor
- Philips Clinical & Medical Affairs Global
Musculoskeletal Pain
Effectiveness of Four Orthotic Insoles on Pain in the Lower Body Associated With Musculoskeletal Stress
This was an open-label, single-centre, parallel-group clinical investigation, to evaluate the effectiveness and in-use tolerability of a range of four orthotic insoles on target areas of pain in the lower body, associated with…
- Trial name
- NCT04746755
- Testing
- Orthotic Insole: Lower Back, Orthotic Insole: Heel, Orthotic Insole: Knee to Heel
- Where
- United Kingdom
- Volunteers
- 145 people, healthy volunteers welcome
- Sponsor
- Reckitt Benckiser Healthcare (UK) Limited
Healthy Volunteers
A Study of Multiple Oral Doses of IX-01 in Healthy Male Subjects
The purpose of this study is to investigate the safety and tolerability of IX-01 after multiple doses, and to determine the PK of IX-01 and activity of CYP3A4.
- Trial name
- NCT02792647
- Testing
- IX-01
- Where
- United Kingdom
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Ixchelsis Limited
Respiratory Syncytial Virus Infections
A Study on the Immune Response and Safety of Vaccine Against Respiratory Syncytial Virus (RSV) Given to Adults 18 to 49 Years of Age at Increased Risk for Respiratory Syncytial Virus Disease, Compared to Older Adults 60 Years of Age and Above
The aim of this study is to demonstrate the immune response and to evaluate the safety of the RSVPreF3 OA investigational vaccine in non-immunocompromised adults 18-49 years of age (YOA), who are at increased risk (AIR) for RSV…
- Trial name
- NCT06389487
- Testing
- RSVPreF3 OA investigational vaccine
- Where
- 52 sites in United States, Australia and 4 more
- Volunteers
- 1,459 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Ventilator-associated Pneumonia
VITAL - VAP Prevention by BIP (Bactiguard Infection Protection) ETT Evac in Belgian ICUs
The study objective is to determine VAP (Ventilator Associated Pneumonia) baseline incidence in the ICU in patients receiving endotracheal tubes with evacuation lumen with and without Bactiguard coating.
- Trial name
- VITAL (NCT04242706)
- Testing
- ETTEvac, BIP ETTEvac
- Where
- 2 sites in Belgium
- Volunteers
- 323 people
- Sponsor
- Bactiguard AB
Obsessive-compulsive Disorder
Efficacy and Safety Study of Low-Dose Ondansetron For Adjunctive Therapy In Adult Patients With Obsessive-Compulsive Disorder
This study is to assess the efficacy and safety of two doses of ondansetron (0.5 mg and 0.75 mg) relative to placebo when administered twice daily as adjunctive therapy for adult patients with Obsessive-Compulsive Disorder (OCD)…
- Trial name
- NCT01275248
- Testing
- Ondansetron
- Where
- 32 sites in United States, Mexico
- Volunteers
- 130 people
- Sponsor
- Transcept Pharmaceuticals
Meningococcal Disease, Meningococcal Meningitis
Immunogenicity and Safety of Different rMenB Plus MenACWY Formulations in Adolescents
The purpose of this phase 2 study is to evaluate the safety, tolerability and immunogenicity of two doses of 4 different investigational MenABCWY combination vaccine when administered to healthy adolescents aged 11-18 years.
- Trial name
- NCT01210885
- Testing
- Meningococcal Vaccine
- Where
- 8 sites in Chile, Colombia and 1 more
- Volunteers
- 495 people, healthy volunteers welcome
- Sponsor
- Novartis Vaccines
Lumbar Spine Degeneration
INFUSE®Bone Graft in Transforaminal Lumbar Interbody Fusion for Degenerative Disease of Lumbosacral Spine
This investigation will provide safety and effectiveness information on the use of INFUSE® Bone Graft with the CAPSTONE® Spinal System and CD HORIZON® Spinal System with a Transforaminal Lumbar Interbody Fusion (TLIF) surgical…
- Trial name
- TLIF (NCT01415908)
- Testing
- INFUSE Bone Graft, Iliac Crest Bone Graft
- Where
- 5 sites in United States
- Volunteers
- 15 people
- Sponsor
- Medtronic Spinal and Biologics
Triglycerides, Weight Gain Trajectory
Effects of RDX-002 on Postprandial Triglycerides in Patients Discontinuing GLP-1 Agonists
The goal of this clinical trial is to learn if drug RDX-002 works to treat high levels of fat (known as triglycerides, or TGs) in the blood in adults. It will also learn about the safety of drug RDX-002.
- Conditions
- Triglycerides, Weight Gain Trajectory, Cholesterol, Elevated
- Trial name
- NCT06640972
- Testing
- RDX-002
- Where
- United States
- Volunteers
- 68 people
- Sponsor
- Response Pharmaceuticals
Herpes Simplex
A Study on the Reactogenicity, Safety and Immune Response of a Targeted Immunotherapy Against HSV in Healthy Japanese Participants Aged 18-40 Years
The purpose of this study is to evaluate the safety, reactogenicity and immunogenicity of 2 formulations of Herpes Simplex Virus (HSV)-Targeted Immunotherapy (HSVTI) in HSV-2 seronegative ethnic Japanese adults aged 18-40 years.
- Trial name
- TH HSV REC-004 (NCT05989672)
- Testing
- HSVTI Formulation 1, HSVTI Formulation 2
- Where
- Japan
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.